aTyr Pharma, Inc. (NASDAQ:ATYR) Stock Short Interest Report for October

Posted by Stanley Muller on Nov 12th, 2026

aTyr Pharma, Inc. (NASDAQ:ATYR – Get Free Report) was the target of a significant drop in short interest during the month of October. As of October 30th, there was short interest totaling 293,448 shares, a drop of 97.1% from the October 15th total of 10,273,700 shares. Based on an average daily volume of 87,073 shares, the days-to-cover ratio is currently 3.4 days. Approximately 12.6% of the company’s shares are short sold.

aTyr Pharma Trading Down 4.2%

NASDAQ:ATYR traded down $0.28 during mid-day trading on Thursday, hitting $6.49. The stock had a trading volume of 13,876 shares, compared to its average volume of 66,589. The company has a 50 day simple moving average of $10.88 and a 200-day simple moving average of $23.26. The stock has a market capitalization of $16.53 million, a price-to-earnings ratio of -0.30 and a beta of 1.04. aTyr Pharma has a 52 week low of $4.07 and a 52 week high of $44.40.

aTyr Pharma (NASDAQ:ATYR – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($7.43) EPS for the quarter, missing the consensus estimate of ($4.00) by ($3.43). The business had revenue of $235.23 million for the quarter, compared to analysts’ expectations of $2.50 million. As a group, equities research analysts anticipate that aTyr Pharma will post -22.96 earnings per share for the current year.

Hedge Funds Weigh In On aTyr Pharma

A hedge fund recently bought a new position in aTyr Pharma stock. Renaissance Technologies LLC purchased a new position in aTyr Pharma, Inc. (NASDAQ:ATYR – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 40,522 shares of the company’s stock, valued at approximately $32,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on ATYR shares. Weiss Ratings lowered aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. Wells Fargo & Company lifted their price target on aTyr Pharma from $1.00 to $4.00 and gave the company an “equal weight” rating in a report on Friday, November 6th. Wall Street Zen upgraded aTyr Pharma to a “hold” rating in a report on Saturday, October 31st. Royal Bank Of Canada cut their price target on shares of aTyr Pharma to $6.00 and set a “sector perform” rating on the stock in a report on Friday, November 6th. Finally, Freedom Broker cut aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $5.00.

Read Our Latest Stock Analysis on aTyr Pharma

aTyr Pharma Company Profile

(Get Free Report)

aTyr Pharma, Inc. (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation. aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.